vascular endothelial growth factor antagonists
Neovascular (wet) age-related macular degeneration (AMD).
Binds to and inactivates vascular endothelial growth factor (VEGF) receptors which normally promote neovascularization and vascular permeability.
Slowed progression of AMD.
Absorption: Action is local following intravitreal injection, minimal systemic absorption occurs.
Distribution: Distribution occurs mainly in the vitreal space.
Metabolism and Excretion: Degraded by proteolytic enzymes. Undergoes passive renal excretion.
Half-life: 4.4 days.
TIME/ACTION PROFILE (improved visual acuity)
|Intravitreal||Within 4 wk||8–12 wk||Maintained throughout treatment|
Ocular/periocular infectionActive intraocular inflammation
Use Cautiously in:
EENT: blurred vision, cataracts, conjunctival hemorrhage, conjunctivitis, corneal abrasion, endophthalmitis (from procedure), eye pain, ↑ intraocular pressure (from procedure), ↑ lacrimation, intraocular inflammation, punctate keratitis, retinal detachment (from procedure), retinal hemorrhage, retinal tear, retinal vascular occlusion, retinal vasculitis, vitreous detachment, vitreous floaters
Misc: hypersensitivity reactions
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Intravitreal (Adults): 6 mg every 4 wk for first 3 doses, then 6 mg every 8–12 wk.
Solution for injection: 6 mg/0.05 mL
Solution is clear to slightly opalescent and colorless to slightly brownish-yellow. Do not administer solutions that are cloudy, discolored, or contain particulate matter. Store in refrigerator; allow to warm to room temperature for up to 24 hr prior to injection. Do not freeze.
Slowing of vision loss.
Nursing Central is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Complete Product Information.